Bone Biologics (BBLG) Long-Term Deferred Tax (2020 - 2022)

Bone Biologics (BBLG) has reported Long-Term Deferred Tax for 3 consecutive years, with $11.0 million the latest figure, recorded in Q4 2022.

• In Q4 2022, Long-Term Deferred Tax fell 41.62% year-over-year to $11.0 million; the TTM figure through Dec 2022 stood at $11.0 million (down 41.62% YoY), while the FY2022 annual figure was $11.0 million, down 41.62% from the prior year.
• Long-Term Deferred Tax slipped to $11.0 million in Q4 2022 per BBLG's latest filing, from $18.8 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $18.8 million in Q4 2021 and bottomed at $8.7 million in Q4 2020.
• Historically, Long-Term Deferred Tax has averaged $12.8 million across 3 years, with a median of $11.0 million in 2022.
• Annual changes were most pronounced in 2021 — Long-Term Deferred Tax jumped 114.8% — and 2022, when it slumped 41.62%.
• Bone Biologics' Long-Term Deferred Tax stood at $8.7 million in 2020, then surged by 114.8% to $18.8 million in 2021, then plunged by 41.62% to $11.0 million in 2022.
• Business Quant data shows BBLG's Long-Term Deferred Tax at $11.0 million in Q4 2022, $18.8 million in Q4 2021, and $8.7 million in Q4 2020.